Cullinan Therapeutics, Inc. - Common Stock (NQ:CGEM)

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

October 01, 2026

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

Performance

52-Week Range 40.8% below 52-week high

13.73

6.7352W Low 23.1952W High

1 Week 13.9% below 1-week high

13.441W Low 15.951W High

Cullinan Therapeutics, Inc. - Common Stock (CGEM) traded between $6.73 and $23.19 over the past 52 weeks and last traded at $13.73, 40.8% below its 52-week high. Over the past week it ranged between $13.44 and $15.95.

Past 12 Months

-11.2%

-32.7%

-23.0%

-8.2%

+35.7%

+77.4%

1W -$1.73

1M -$6.67

3M -$4.10

6M -$1.22

YTD +$3.61

1Y +$5.99

CGEM was +77.4% over the past year, -8.2% over six months, +35.7% year to date, -11.2% in the last week.

12 Months vs Market

CGEM

+77.4%

DIA

+11.7%

SPY

+15.8%

QQQ

+20.2%

IWM

+9.6%

Over the past 12 months CGEM returned +77.4% versus DIA (Dow) +11.7%, SPY (S&P 500) +15.8%, QQQ (Nasdaq 100) +20.2% and IWM (Russell 2000) +9.6%.

Volume & Liquidity 0.04× 3-mo avg

Today 36,017 3-mo avg 875.4K

714.2K

1.3M

875.4K

972.2K

YTD

907.2K

964.2K

CGEM most recently traded 36,017 shares against a 3-month average daily volume of 875.4K.

More News

Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049 ↗

September 28, 2026

Via MarketBeat

September 24, 2026

Cullinan Therapeutics (NASDAQ:CGEM) Shares Jump on Inline Q2 Earnings and Pipeline Milestones ↗

August 06, 2026

Via Chartmill

Cullinan Therapeutics (NASDAQ:CGEM) Posts Narrower Q1 Loss, Eyes Key Clinical Data Catalysts ↗

May 07, 2026

Via Chartmill

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

September 21, 2026

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

September 14, 2026

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

September 13, 2026

From Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. and Cullinan Therapeutics, Inc.

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

September 10, 2026

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer

August 19, 2026

From Taiho Oncology, Inc.

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

August 12, 2026

From Taiho Oncology, Inc.

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 06, 2026

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

July 28, 2026

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

June 10, 2026

Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket ↗

June 08, 2026

Via Benzinga

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

June 06, 2026

Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

May 26, 2026

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

May 19, 2026

Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

May 18, 2026

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 07, 2026

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

April 28, 2026

From Taiho Oncology, Inc.

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

March 10, 2026

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

February 24, 2026

Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit

February 18, 2026